Get the Stockscreener App
12.17
5.88%
-0.83
Forte Biosciences Inc stock is traded at $12.17, with a volume of 25,713.
It is down -5.88% in the last 24 hours and down -41.09% over the past month.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
See More
Previous Close:
$13.00
Open:
$12.79
24h Volume:
25,713
Relative Volume:
0.05
Market Cap:
$83.11M
Revenue:
-
Net Income/Loss:
$-31.48M
P/E Ratio:
-11.70
EPS:
-1.04
Net Cash Flow:
$-28.71M
1W Performance:
-23.00%
1M Performance:
-41.09%
6M Performance:
+4.11%
1Y Performance:
-16.31%
1-Day Range:
$12.01
$14.04
1-Week Range:
$12.01
$16.25
52-Week Range:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
12.17 | 83.11M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.31 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.13 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.13 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.76 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.68 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - MarketBeat
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings -February 03, 2025 at 09:03 am EST - Marketscreener.com
(FBRX) Proactive Strategies - Stock Traders Daily
TD Cowen initiates Forte Biosciences stock with Buy rating - MSN
Forte Biosciences expands equity incentive plan By Investing.com - Investing.com Australia
Forte Biosciences expands equity incentive plan - MSN
Traders Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World
Forte Biosciences (NASDAQ:FBRX) Coverage Initiated by Analysts at TD Cowen - Defense World
TD Cowen initiates Forte Biosciences stock with Buy rating By Investing.com - Investing.com Australia
Atopic Dermatitis Drugs Market Trends Analysis Report - GlobeNewswire
(FBRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX) - Defense World
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
(FBRX) Technical Data - Stock Traders Daily
Investors Purchase Large Volume of Put Options on Evelo Biosciences (NASDAQ:EVLO) - Defense World
Investors Buy High Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World
(FBRX) Long Term Investment Analysis - Stock Traders Daily
Why Forte Biosciences (FBRX) Stock Is Trading Lower - Benzinga
CBD Life Sciences Inc. (OTCMKTS:CBDL) Short Interest Up 8,233.3% in November - Defense World
Traders Buy Large Volume of Call Options on Quantum-Si (NASDAQ:QSI) - Defense World
Invea Therapeutics Strengthens Leadership with Appointment of Dr. Stephen Doberstein, Veteran Biotech Executive, to Its Board of Directors - The Manila Times
Trading (FBRX) With Integrated Risk Controls - Stock Traders Daily
FBRX Stock Soars to 52-Week High, Reaching $24.46 By Investing.com - Investing.com Nigeria
Forte Biosciences’ $53 Million Equity Financing - Global Legal Chronicle
Biopharma Takes on Deadly Brain Cancer After Decades of Failure - BioSpace
(FBRX) Trading Report - Stock Traders Daily
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going - MSN
FBRX Stock Soars to 52-Week High, Reaching $21.47 - Investing.com India
FBRX Stock Soars to 52-Week High, Reaching $21.47 By Investing.com - Investing.com UK
Forte Biosciences Sets R&D Day to Showcase FB102 Autoimmune Treatment Pipeline | FBRX Stock News - StockTitan
Forte Biosciences CFO acquires $124,997 in company stock By Investing.com - Investing.com Canada
Forte Biosciences CFO acquires $124,997 in company stock - Investing.com
More than $50M raised by publicly traded drug developer - The Business Journals
Dallas' Forte Biosciences Announces $53M Private Placement From Leading Healthcare Investors - dallasinnovates.com
Forte Biosciences Stock More Than Doubles On Oversubscribed $53M Private Placement: Retail Goes Wild - MSN
EDIT Stock Drops Amid Market Volatility in Biotech Sector - GuruFocus.com
Cidara’s $100M PIPE; Pyxis Oncology’s stock falls on Phase 1 data - Endpoints News
Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn
Forte Biosciences secures $53 million in funding By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com
Artelo Biosciences (ARTL) Stock Surges Amid Strong Buy Ratings - GuruFocus.com
5 Stocks Retail Investors Are Most Bullish On At Mid-Day - MSN
Forte Biosciences Secures $53M for FB102 Advancements - TipRanks
Terns Pharmaceuticals (TERN) Stock Drops Over 5% Amidst Mixed In - GuruFocus.com
Forte Biosciences Shares Are Soaring Today: What's Going On? - Benzinga
Crude Oil Moves Lower; Williams-Sonoma Shares Gain After Q3 Results - Benzinga
Forte Biosciences secures $53 million in funding - Investing.com India
Forte Biosciences More Than Doubles on $53M Private Placement - MarketWatch
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Forte Biosciences Inc Stock (FBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wagner Paul A. | SEE REMARKS |
Jan 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
78,720 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Nov 21 '24 |
Buy |
5.55 |
22,514 |
124,998 |
30,776 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '24 |
Option Exercise |
0.00 |
375 |
0 |
8,395 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '24 |
Option Exercise |
0.00 |
1,250 |
0 |
77,568 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jul 01 '24 |
Option Exercise |
0.00 |
9,375 |
0 |
203,849 |
| Wagner Paul A. | SEE REMARKS |
Jul 01 '24 |
Option Exercise |
0.00 |
31,250 |
0 |
1,910,424 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Apr 01 '24 |
Option Exercise |
0.00 |
9,375 |
0 |
197,819 |
| Wagner Paul A. | SEE REMARKS |
Apr 01 '24 |
Option Exercise |
0.00 |
31,250 |
0 |
1,881,627 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):